Alain Sanchez, MD
@lain_sanchez
Followers
262
Following
3K
Media
196
Statuses
840
Rheumatologist and Internist @ABCcentromedico | Professor @TECccm Former Research Fellow, Division of rheumatology @MayoClinic, Rochester, MN
Rochester, MN
Joined September 2013
The most dangerous phrase in our language is “we have always done it this way”
0
2
11
Thanks so much for this opportunity!! https://t.co/9YxL9bodhT
NEW EPISODE! Alain Sanchez-Rodriguez, MD, joins the podcast to discuss delays in #lupus diagnosis & care based on findings from the Lupus Midwest Network (LUMEN)🎙️LISTEN NOW → https://t.co/8UZWFRmHJJ
@ACR_Journals
0
1
4
Over 20 years have passed since the ACR last issued a broad treatment guideline for #SLE. In our NEWEST episode, Lisa R. Sammaritano, MD, summarizes the major updates in the soon-to-be-released 2025 guideline.🎙️LISTEN → https://t.co/Z38VEjrlLh
0
9
14
#ESOC2025 🏃🏻♀️ESCAPE MEVO sub analysis 👉🏻 prognosis by image 🧠 👉🏻EVT <12 hs not > good functional outcome 👉🏻 Good collateral status > benefit 👉🏻 ⏱️<180 min > benefit
1
31
72
1/ 🧵The 2024 ACR Guidelines for Lupus Nephritis (LN) are here! Big shifts in screening, combo therapy, and steroid minimization. Let's break it down. Full text:
1
55
128
Now published simultaneously in AC&R + A&R, the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis See ACR guideline page for resources - https://t.co/zhvkPxCTcr DOI link - https://t.co/Hllq83J7Kc Download the article - https://t.co/uAJ7JaO7pz
1
72
184
Welcome Jaime! 🤩⭐️🤩⭐️
2
2
40
Rheumatologist when someone automatically calls an ANA (+) “undifferentiated connective tissue disease”
2
7
29
NEW! Curious about how genetics influence autoimmune disease risk? Tune in & hear from @HocaogluMd, who dives into the study of antinuclear antibody production using data from the All of Us Research Program → https://t.co/hT34GkajXp
@ACR_Journals
0
6
8
🔟 Final Takeaways ✅ Obi improved renal outcomes in active LN ✅ Steroid-sparing effect (more Obi pts tapered to ≤7.5 mg/day) ✅ Proteinuria reduction = better long-term kidney survival ✅ Infections (esp. COVID-19) are a key safety concern
2
5
19
🚨 Breaking down the REGENCY trial 🚨 A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️
3
36
111
🚨 New Review Alert! 🚨 Dive into the evolving landscape of glucocorticoid therapy for lupus nephritis: 🔍 Historical shifts from high-dose to safer, low-dose strategies 🧬 Mechanisms, efficacy, & risks explored ⚖️ Balancing treatment efficacy with long-term safety
Now online in @NDTsocial Optimal Glucocorticoid Therapy in Lupus Nephritis 🧐The review examines different dosing strategies, including IV pulse and oral regimens, and presents evidence of their efficacy and safety. ▶️ https://t.co/GHdRStcr69
1
13
44
In a new summary of its 2024 Guideline for the Screening, Treatment, and Management of Lupus Nephritis, the ACR offers 41 recommendations for clinicians treating the condition. First author, Dr. Lisa Sammaritano, tells us more. #lupusnephritis
1
20
44
Usually everything from @drlalonares is quite interesting. This was not the exemption #ACR24
👉🏼Presenting our recent work: Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease @FuruzawaJanette
#ACR24 #ACR2024 #IgG4RD @IgG4ward @ReumaJoven @PanlarJ
0
1
2
0
100
275
We are honored to host tonight's Hess Reception, celebrating leaders in #lupusresearch. This year’s honorees are Drs. Rovin, Duarte-García, and Askanase. We’re proud to recognize their contributions to advancing lupus research. #LFAatACR #ACR24
1
14
63
Congratulations!!! 🤩🤩🤩🎉🎉🎉 to one of the most brilliant and hardworking colleagues and friends I’ve met.
Thank you @RheumResearch Please continue changing carriers with more funding opportunities for research in early scholars. #ACR24
1
0
3
Congratulations to Dr. Alí Duarte-García, MD, MS @AliDuarteMD for receiving the 2024 Mary Betty Stevens, MD, Young Investigator Prize. Dr. Duarte has made important contributions to understanding the epidemiology of systemic lupus erythematosus and antiphospholipid syndrome.
19
8
69
Care pathways among patients with SLE in the Lupus Midwest Network registry: • ~1/4 were initially seen by nephrology or dermatology • 1/4 patients had delays in access to SLE-specialized care, which were assoc. with damage • Hematologic or aPL antibodies domains, and fewer
0
4
5
Muchas felicidades!! 🎉🎉🎉 Enhorabuena 👏 👨🎓
Today was a very important day. I received my master's degree from the @MayoGradSchool! I'm very happy to have shared this moment with my family, mentors, and friends. Thanks to all those who were with me through this journey!
1
0
5